| Name | Etidronic acid |
| Description | Etidronic acid (HEDP) is a diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover. |
| In vitro | Etidronate inhibits directly osteoclastic bone-resorbing activity by pit assay. Etidronate also directly induces apoptosis and disrupts actin rings in osteoclasts. [1] |
| In vivo | Etidronate, when administered s.c. repeatedly at 10 or 40 mg/kg/day, gradually suppresses the adjuvant-induced allodynia In the rats with adjuvant arthritis, as assessed by 10-g von Frey hair. Etidronate (10-40 mg/kg/day) suppresses the adjuvant-induced mechanical allodynia in rat hindpaw. Etidronate (5–10 mg/kg/day) dose-dependently prevents the decrease in bone mineral density (BMD) in the proximal tibia of the arthritic rats. [2] Etidronate inhibits the histidine decarboxylase induction, but not the other inflammatory reactions induced by alendronate. Etidronate (unlike clodronate) also inhibits alendronate-induced BP-line formation in mice (even at 40 mmol/kg). Etidronate (160 mmol/kg) also inhibits the physicochemical changes in the tibia induced by six, weekly injections of alendronate. [3] Etidronate (10 mg/kg) combined with Calcitriol after subtotal nephrectomy (SNx) significantly inhibits thoracic and abdominal aortic calcification 3 weeks after the operation in rats. [4] Etidronate (5 mg/kg or 10 mg/kg) significantly reduces the thoracic and abdominal aortic calcification induced by calcitriol in the renal failure rat. Etidronate (5 mg/kg or 10 mg/kg) also reduces the dysfunction in aortic contraction. Etidronate (5 mg/kg) reverses the reduction in the aortic expression of matrix Gla protein mRNA observed in nephrectomized rats. [5] |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (9.71 mM), Sonication is recommended.
DMSO : 45 mg/mL (218.41 mM), Sonication is recommended.
|
| Keywords | V-type proton ATPase catalytic subunit | protein tyrosine phosphatase(PTP) | Paget's disease | osteoporosis | MCF-7 | Inhibitor | inhibit | HAP | Etidronic acid | arterial calcification | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Lamivudine | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Cosmetic Ingredient Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
